The Ohio State University

Hu Lab

Research Interests:

  • Role of solute carriers in renal and hepatic anticancer drug clearance, chemotherapy-induced toxicity profiles
  • Drug transporter regulation
  • Preclinical pharmacology of tyrosine kinase inhibitors
  • Pharmacokinetic variability of anticancer agents
  • Genetic factors contributing to inter-individual variability in anticancer drug disposition

Many chemotherapeutic agents can cause neurological side effects, impacting quality of life. The incidence of chemotherapy-induced peripheral neuropathy (CIPN) is particularly high with agents such as paclitaxel and oxaliplatin, occurring in up to 80% of patients receiving such agents. There are currently no effective strategies for prevention of CIPN, and rationally designed intervention studies are needed to better address this gap. Dr. Hu’s research interests are focused on the development of transport modulators that could be used in conjunction with neurotoxic chemotherapy to understand drug transporter regulation mechanism; to determine the role of drug transporters on anticancer agents induced inter-individual pharmacokinetic variability, antitumor efficacy and drug to drug interaction; to evaluate contribution of solute carrier to chemotherapy-induced CIPN; and to develop preclinical and clinical studies with potential implications to ameliorate the incidence and severity of debilitating side effects of cancer drugs.

Google Scholar Profile

Biosketch:

Dr. Hu obtained her PhD degree in Pharmaceutical Sciences from West Virginia University and completed her postdoctoral training at Johns Hopkins University and St. Jude Children’s Research Hospital. She was subsequently employed as research scientist at both St. Jude and the Ohio State University (OSU) prior to her current faculty appointment in the Division of Pharmaceutics and Pharmacology at OSU. Dr. Hu has published more than 60 peer-reviewed research articles, reviews and textbook chapters, and is actively involved in editorial/review activities with various journals. She has presented numerous invited talks at national and international scientific meetings and organizations. As an active member of American Society of Clinical Pharmacology and Therapeutics (ASCPT), Dr. Hu is the past Chair of the Membrane Transporter Community within the Translation and Precision Medicine Network, and 2021 ASCPT Darrell Abernethy Early Stage Investigator Awardee. Dr. Hu has an established mentorship record with undergraduate, graduate students and postdoctoral PhD level researchers.

Trainees:

Yue Xu, PhD – Post-Doctoral Researcher
Anika Chowdhury-Graduate Student
Brandon Steiger – Graduate Student
Nick Kleinert-Graduate Student

Publications:

  • Drabison T, Boeckman M, Yang Y, Huang KM, de Bruijn P, Nepal MR, Silvaroli JA, Chowdhury AT, Eisenmann ED, Cheng X, Pabla N, Mathijssen RHJ, Baker SD, Hu S, Sparreboom A, Talebi Z. Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen. Cancer Res Commun. 4(9):2489-2497,2024. Link (IF 2.0)
  • Taheri H., Jin Y., Hu P., Ahmed E., Li Y., Sparreboom A., and Hu S.  Quantification of the aromatase inhibitor letrozole and its carbinol metabolite in mouse plasma by UHPLC-MS/MS J Chromatogr. B. 1238: 124106, 2024 Link (IF 3.205)
  • Buck S, Talebi Z, Drabison T, Jin Y, Gibson A, Hu P, de Bruijn P, Hu S, van Weerden W, Koolen S, De Wit R, Sparreboom A, Mathijssen R, Eisenmann E. Darolutamide does not interfere with OATP-mediated uptake of docetaxel. Int J of Cancer. 155(2): 314-323, 2024. Link (IF 7.396)
  • Li Y, Drabison T, Kazuki Y, Kobayashi K, Fujita K, Xu X, Jin Y, Ahmed E, Li J, Eisenmann E, Baker SD, Cavaletti G, Sparreboom A, Hu S. Vincristine Disposition and Neurotoxicity in Humanized CYP3A5 Mice. Drug Metabolism and Disposition. 52(2):80-85. Link (IF 3.922)
  • Li Y, Drabison T, Nepal M, Ho RH, Leblanc AF, Gibson AA, Jin Y, Yang W, Huang KM, Uddin ME, Chen M, DiGiacomo DF, Chen X, Razzaq S, Tonniges JR, McTigue DM, Mims AS, Lustberg MB, Wang Y, Hummon AB, Evans WE, Baker SD, Cavaletti G, Sparreboom A, Hu S. Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy. JCI Insight. 2023 Jul 24;8(14):e164646. Link (IF, 8.04)
  • Anabtawi N, Drabison T, Hu S, Sparreboom A, Talebi Z. The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature. Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):459-468. doi: 10.1080/17425255.2022.2113380.
  • Anderson JA, Huang KM, Lustberg MB, Sparreboom A, Hu S. Solute carrier transportome in chemotherapy-induced adverse drug reactions. Rev Physiol Biochem Pharmacol. 2022;183:177-215. doi: 10.1007/112_2020_30.
  • Brouwer KLR, Evers R, Hayden E, Hu S, Li CY, Meyer zu Schwabedissen HE, Neuhoff S, Oswald S, Piquette-Miller M, Saran C, Sjöstedt N, Sprowl JA, Stahl SH, Yue W. Regulation of drug transport proteins – from mechanisms to clinical impact: A white paper on behalf of the international transporter consortium. Clin Pharmacol Ther. 2022 Sep;112(3):461-484. doi: 10.1002/cpt.2605.
  • Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED. Itraconazole-induced increases in gilteritinib exposure are mediated by CYP3A and OATP1B. Molecules. 2022 Oct 12;27(20):6815. doi: 10.3390/molecules27206815.
  • Hafey MJ, Aleksunes LM, Bridges CC, Brouwer KR, Chien H-C, Leslie EM, Hu S, Li Y, Shen J, Sparreboom A, Sprowl JA, Tweedie D, Lai Y. Transporters and toxicity: insights from the International Transporter Consortium workshop 4. Clin Pharmacol Ther. 2022 Sep;112(3):527-539. doi: 10.1002/cpt.2638.
  • Hove VN, Anderson K, Hayden ER, Pasquariello KZ, Gibson AA, Shen S, Qu J, Jin Y, Miecznikowski JC, Hu S, Sprowl JA. Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake. Mol Pharmacol. 2022 Jun;101(6):381-389. doi: 10.1124/molpharm.121.000287.
  • Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S. Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Nov 1;1210:123437. doi: 10.1016/j.jchromb.2022.123437.
  • Li Y, Jin Y, Taheri H, Schmidt KT, Gibson AA, Buck SAJ, Eisenmann ED, Mathijssen RHJ, Figg WD, Baker SD, Sparreboom A, Hu S. A Metabolomics approach for predicting OATP1B-Type transporter-mediated drug-drug interaction liabilities. Pharmaceutics. 2022 Sep 13;14(9):1933. doi: 10.3390/ pharmaceutics14091933.
  • Nepal MR, Taheri H, Li Y, Uddin ME, Jin Y, DiGiacomo DF, Gibson AA, Lustberg MB, Hu S, Sparreboom A. Targeting OCT2 with duloxetine to prevent oxaliplatin-induced peripheral neurotoxicity. Cancer Res Commun. 2022 Nov;2(11):1334-1343. doi: 10.1158/2767-9764.crc-22-0172.
  • Uddin ME, Eisenmann ED, Huang KM, Garrison DA, Talebi Z, Gibson AA, Jin Y, Nepal M, Bonilla IM, Fu Q, Miller A, Tarasovc M, Jay CE, Cui X, Einolf HJ, Pelise RM, Smith S, Radwanski P, Sweet DH, König J, Fromm MF, Carnes CA, Hu S, Sparreboom A. MATE1 deficiency exacerbates dofetilide-induced proarrhythmia. Int J Mol Sci. 2022 Aug 3;23(15):8607. doi.org/10.3390/ijms23158607.